Ultragenyx (RARE) Pharmaceutical announced the submission of a Biologics License Application, BLA, to the U.S. Food and Drug Administration seeking accelerated approval for UX111, ABO-102, AAV gene therapy as a treatment for patients with Sanfilippo syndrome type A
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RARE:
- Ultragenyx price target lowered to $102 from $105 at JPMorgan
- Ultragenyx participates in a conference call with JPMorgan
- Ultragenyx price target raised to $121 from $109 at Canaccord
- Ultragenyx price target raised to $95 from $82 at H.C. Wainwright
- 3 Best Stocks to Buy Now, 11/6/2024, According to Top Analysts
Questions or Comments about the article? Write to editor@tipranks.com